IONIS PHARMACEUTICALS Q1 FY26 earnings call IONS

Ionis is on track for the independent launch of olezarsen in severe hypertriglyceridemia (SHTG), following Priority Review by the FDA with a PDUFA date of June 30. Extensive market research with high-volume lipid specialists, cardiologists, and endocrinologists consistently showed that preventing pancreatitis is the key treatment goal in SHTG, and current options are insufficient. HCPs expressed high intent to prescribe olezarsen across various patient types, with initial use expected for individuals with triglyceride levels above 880 mg/dL or above 500 mg/dL with a history of acute pancreatitis or other high-risk comorbidities. The company has set a new annual wholesale acquisition cost of $40,000, integrating olezarsen into 2027 payer contracting cycles.

The DAWNZERA launch is gaining significant momentum in the U.S., largely in a switch market for Hereditary Angioedema (HAE). The company observes increasing adoption across all patient segments: those switching from existing prophylactic therapies, those previously using on-demand treatment, and treatment-naive patients. The free trial program has been effective with high conversion rates. Feedback from both physicians and patients is consistently positive, highlighting DAWNZERA's strong efficacy, differentiated RNA-targeted mechanism, positive switch data, and patient-friendly profile including a self-administered auto-injector. Repeat prescribers are growing, indicating substantial patient benefit, and the launch fundamentals suggest significant contribution to commercial revenue in 2026 and beyond.

Ionis is preparing for its first independent launch from its neurology portfolio with Zilganersen for Alexander's disease, following FDA Priority Review with a PDUFA date of September 22. The expanded access program is underway. Commercial efforts focus on strengthening relationships with leukodystrophy and rare neurology HCPs, advancing partnerships with patient advocacy groups, and ensuring support infrastructure for diagnosis, treatment, and ongoing care. The medical affairs team is engaging with top centers to build awareness. The company estimates approximately 300 Alexander's disease patients in the U.S., with about 50% identified, and is expanding efforts to identify more patients.

The partnered pipeline continues to advance towards multiple value-driving events. Bepirovirsen (chronic hepatitis B, partnered with GSK) is on track for launch in the U.S. and Japan this year, having received Breakthrough Therapy designation and Priority Review with an October 26 PDUFA date. GSK will present Phase III results at EASL. Additionally, data from two major cardiovascular outcome trials are expected this year: the pelacarsen Lp(a) HORIZON trial and the eplontersen Cardio Transform trial in transthyretin-mediated cardiomyopathy. These programs, along with Bepirovirsen, contribute to an expectation of five partner-led launches by the end of 2027, creating diversified royalty and milestone streams.

Ionis' Q1 performance underscores the value of its diversified revenue model, combining growing commercial revenue with substantial and recurring R&D revenue from partner programs. The company ended the quarter with approximately $1.9 billion in cash, even after repaying $633 million in convertible notes. This strong balance sheet and prudent fiscal management enable strategic investments in ongoing and planned launches and pipeline advancement. The financial outlook reflects accelerating commercial launches, a progressing pipeline, and a diversified revenue base, positioning the company for continued growth and maintaining its target for cash flow breakeven in 2028.